Allogene Therapeutics, Inc.
ALLO
$2.22
-$0.01-0.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 25.90% | 25.20% | 15.22% | 13.68% | 21.29% |
| Total Depreciation and Amortization | -9.38% | -9.71% | -11.25% | -7.47% | -3.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -41.33% | -46.74% | -26.01% | -18.94% | -29.17% |
| Change in Net Operating Assets | 56.14% | 84.62% | 76.67% | 20.18% | -16.39% |
| Cash from Operations | 25.49% | 27.13% | 24.46% | 13.07% | 15.75% |
| Capital Expenditure | 44.38% | -4.05% | -312.44% | -60.53% | 54.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 25.61% | 32.30% | -77.12% | -17.07% | -53.65% |
| Cash from Investing | 26.25% | 32.49% | -77.72% | -17.60% | -53.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -79.68% | -80.58% | -83.48% | 29.04% | 19.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 202.98% | 202.98% | 202.98% | -- | -- |
| Cash from Financing | -74.15% | -74.76% | -77.78% | 34.93% | 21.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -196.46% | 25.45% | -843.82% | 85.42% | -137.35% |